SCHEMBL3801955

SCHEMBL3801955

C=CCSc1ncccc1C(=O)N1CCN(CC(=O)N2CCN(C3CCC3)CC2)CC1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
MEN1 O00255 1/20 0.41
POLB P06746 1/20 0.41
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
HRH3 Q9Y5N1 5/20 0.39
HSD11B1 P28845 1/20 0.39
PARP1 P09874 1/20 0.38
TP53BP1 Q12888 1/20 0.38
L3MBTL3 Q96JM7 1/20 0.38
KDM4E B2RXH2 5/20 0.38
ALDH1A1 P00352 3/20 0.38
TDP1 Q9NUW8 1/20 0.36
CHRM2 P08172 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3769123 0.88 HSD11B1 (0.44) KMT2AL3MBTL1MEN1POLBCYP2C19
SCHEMBL13005958 0.86 KMT2A (0.55) KMT2AL3MBTL1MEN1HRH3PARP1
SCHEMBL3767714 0.83 HRH3 (0.50) KMT2AL3MBTL1MEN1POLBHRH3
SCHEMBL3774253 0.81 HRH3 (0.44) KMT2AHRH3KDM4EALDH1A1
SCHEMBL3770169 0.78 KDM4E (0.46) KMT2AL3MBTL1MEN1HRH3KDM4E
SCHEMBL4985760 0.78 HSP90AB1 (0.42) CYP1A2CYP3A4CYP2C9CYP2C19CHRM2
SCHEMBL3769925 0.76 HRH3 (0.52) KMT2AL3MBTL1MEN1POLBHRH3
SCHEMBL3773393 0.76 LMNA (0.43) KMT2AMEN1HRH3KDM4EALDH1A1
SCHEMBL3767998 0.75 L3MBTL1 (0.57) L3MBTL1POLBHRH3PARP1KDM4E
SCHEMBL3773954 0.74 MEN1 (0.62) KMT2AL3MBTL1MEN1CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 KMT2A 242/4885L3MBTL1 1468/4885MEN1 3270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.